MIT’s interdisciplinary Media Lab, famous for its blue-sky research on the crea-tive use of technology, is now being piloted by an aero-astro alumnus from the commercial side of high tech. Frank Moss, SM ‘72, PhD ‘77, the new director of the Media Lab, served as CEO of information tech-nology management software provider Tivoli Systems and cofounded three high-tech companies, including Web services pioneer Bowstreet. He also delved into biotech, cofounding Infinity Pharmaceuticals to pursue cancer drug discovery.
Big thinking at the Media Lab has led to such achievements as MPEG video compression and the founding of E Ink, a company that provides electronic-paper display technologies. But its researchers’ freedom has depended on an unusual funding structure. “We have a system whereby sponsors join up as a member of the lab community,” says Moss, and get unrestricted access to the lab’s intellectual property.
Moss believes his commercial experience will help the Media Lab cultivate strong working relationships with sponsors. “We need to understand what corporations are looking for when they make an investment with an academic institution like the Media Lab,” he says. “Having been part of that world, I can put myself in their shoes and [make] it more compelling for them to invest their time and effort.”
Moss holds MIT’s Jerome B. Wiesner Chair in Media Technology and has been named Professor of the Practice of Media Arts and Sciences, a position reserved for distinguished practitioners.
Lab cofounder Nicholas Negroponte stepped down as chairman in February to focus on his nonprofit, One Laptop per Child (OLPC). Ex–lab director Walter Bender is on leave to serve as OLPC’s president.
Keep Reading
Most Popular

Why China is still obsessed with disinfecting everything
Most public health bodies dealing with covid have long since moved on from the idea of surface transmission. China’s didn’t—and that helps it control the narrative about the disease’s origins and danger.

Anti-aging drugs are being tested as a way to treat covid
Drugs that rejuvenate our immune systems and make us biologically younger could help protect us from the disease’s worst effects.

These materials were meant to revolutionize the solar industry. Why hasn’t it happened?
Perovskites are promising, but real-world conditions have held them back.

A quick guide to the most important AI law you’ve never heard of
The European Union is planning new legislation aimed at curbing the worst harms associated with artificial intelligence.
Stay connected

Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.